Cullinan Therapeutics, Inc.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
None right now.
Trials
- CGEMCullinan Therapeutics Inc.10Calm
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Running, no new patientsPhase 1/2284 patientsMain results: Oct 13, 2025 - CGEMCullinan Therapeutics Inc.0Calm
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Signing up patientsPhase 1/2275 patientsMain results: Dec 30, 2029
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
4 sales (0 not pre-planned) · 0 purchases
- Michaelson JenniferChief Scientific Officer · Nov 5, 2026Sold 4,000 sharesabout $49 thousand · pre-planned
- Michaelson JenniferChief Scientific Officer · Sep 8, 2026Sold 8,000 sharesabout $173 thousand · pre-planned
- Michaelson JenniferChief Scientific Officer · Aug 13, 2026Sold 30,000 sharesabout $608 thousand · pre-planned
- Michaelson JenniferChief Scientific Officer · Jul 6, 2026Sold 8,000 sharesabout $143 thousand · pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Shared information with investors; Other newsNews report (8-K)Nov 9, 2026
- Shared information with investors; Other newsNews report (8-K)Nov 4, 2026
- Shared information with investors; Other newsNews report (8-K)Oct 2, 2026
- Shared information with investors; Other newsNews report (8-K)Sep 24, 2026
- Shared information with investors; Other newsNews report (8-K)Sep 14, 2026
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.